Cat. No.: HY-N0026

2'-Acetylacteoside

(Synonyms: 2'-AA)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.73%
CAS No.: 94492-24-7
Formule: C₃₁H₃₈O₁₆
Masse moléculaire:666.62

Stockage:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

2'-Acetylacteoside Chemical Structure

CAS No.: 94492-24-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[2]

MAO-B

NF-κB

IKKβ

Voir tous les produits spécifiques à Isoform Monoamine Oxidase :

MAO-A
MAO-B

Voir tous les produits spécifiques à Isoform TNF Receptor :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform IKK :

In Vitro

2'-Acetylacteoside (10^-7-10^-5 mol/L; 0.5 h, 24 h, 6 days) inhibits RANKL-induced osteoclast differentiation of RAW264.7 cells and down-regulates the expression of key proteins in the RANKL/RANK/TRAF6-mediated NF-κB/NFATc1 pathway^[1].
2'-Acetylacteoside binds to Akt3 protein in cultured adult SVZ-derived NSCs, protecting it from protease degradation^[2].
2'-Acetylacteoside (5-40 μM; 24 h) promotes proliferation of OGD/R-treated adult SVZ-derived NSCs^[2].
2'-Acetylacteoside (10 μM; 24 h) enhances the proliferation of OGD/R-treated adult SVZ-derived NSCs in vitro, as shown by a significant increase in EdU-positive cells^[2].
2'-Acetylacteoside (10 μM) promotes differentiation of OGD/R-treated adult SVZ-derived NSCs into immature neurons (DCX-positive) in vitro, without affecting gliogenesis^[2].
2'-Acetylacteoside (10 μM) promotes proliferation and neurogenesis of OGD/R-treated adult SVZ-derived NSCs in vitro via activation of the PI3K/Akt pathway, as shown by increased p-Akt, p-CREB, DCX, and NeuN expression^[2].
2'-Acetylacteoside alters gene expression in OGD/R-treated adult SVZ-derived NSCs in vitro, with significant enrichment of differentially expressed genes in the PI3K/Akt signaling pathway, and up-regulates neurogenesis-related genes including VEGFα, Errb4, Col1a1, and Igfbp5^[2].
2'-Acetylacteoside potently inhibited purified MAO-B enzyme in vitro with an IC₅₀ of 17.71 μM and acted as a reversible mixed inhibitor with high affinity for free MAO-B (Ki = 13.81 μM)^[3].
2'-Acetylacteoside (25-100 μM) scavenges superoxide radicals in a concentration-dependent manner in a cell-free in vitro system^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

cultured adult subventricular zone (SVZ)-derived neural stem cells (NSCs) under oxygen-glucose deprivation/reoxygenation (OGD/R) conditions
Concentration:

5, 10, 20, 40 μM (post-OGD/R incubation); 10 μM (optimal, 24 h incubation)
Incubation Time:

24 h (optimal concentration incubation); 2 h (CCK-8 solution incubation)
Result:

Increased NSC viability significantly at all tested concentrations, with 10 μM showing the most potent effect on proliferation.
Reached the highest proliferation rate 24 h post-treatment.

Cell Proliferation Assay^[2]

Cell Line:

cultured adult subventricular zone (SVZ)-derived neural stem cells (NSCs) under oxygen-glucose deprivation/reoxygenation (OGD/R) conditions
Concentration:

10 μM (post-OGD/R incubation); 50 μM (EdU medium)
Incubation Time:

24 h (post-OGD/R incubation); 2 h (EdU medium incubation)
Result:

Increased the number of EdU-positive cells significantly compared to the OGD/R-only group, with approximately 30% of control cells being EdU-positive and OGD/R treatment already increasing proliferative capacity.

Western Blot Analysis^[2]

Cell Line:

Mouse neural stem cells (NSCs)
Concentration:

10 μM
Incubation Time:

24 h
Result:

Upregulated the expression of p-Akt, p-CREB, DCX, and NeuN.

In Vivo

2'-Acetylacteoside (2'-AA) (10-40 mg/kg/day; p.o.; daily; 12 weeks) exhibits significant anti-osteoporotic activity in ovariectomized mice, all doses improving trabecular bone microarchitecture and biomechanical strength via inhibition of the RANKL/RANK/TRAF6-mediated NF-κB/NFATc1 pathway^[1].
2'-Acetylacteoside (2'-AA) (total glycosides of Cistanche deserticola, p.o.) was detected in brain tissue, and specifically binds to the central target MAO‑B in the brain as determined by UPLC-Q-Exactive-Orbitrap MS^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming (female, 8-week-old, 26 g, osteoporosis induced by bilateral ovariectomy)^[1]
Dosage:

10 mg/kg/day; 20 mg/kg/day; 40 mg/kg/day
Administration:

p.o.; daily; 12 weeks
Result:

Left body, uterus, and vagina weights unchanged in OVX mice.Enhanced femoral mechanical properties, trabecular BMD, BMC, TMC, BVF, Tb.Th, and Tb.N.Reduced trabecular separation across all doses.
Inhibited serum TRAP, cathepsin K, and DPD activities at 40 mg/kg/day.
Diminished bone resorption markers significantly at lower doses.
Showed no significant effect on bone formation markers (ALP, BGP).
Downregulated RANK, TRAF6, IKKβ, NF‑κB, and NFATc1 expression, blocking the RANKL/RANK/TRAF6‑mediated NF‑κB/NFATc1 pathway.

Chemical Information

CAS No. 94492-24-7
Appearance Solid
Masse moléculaire 666.62
Formule C₃₁H₃₈O₁₆
Color Off-white to light yellow
SMILES

OC1=CC=C(/C=C/C(O[C@H]2[C@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](OC(C)=O)[C@H](OCCC4=CC=C(O)C(O)=C4)O[C@@H]2CO)=O)C=C1O
Synonyms

2'-AA
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Neurotox Res

Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]

2026 Mar 19;44(2):12. PMID: 41854817

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (150.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : ≥ 100 mg/mL (150.01 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5001 mL

7.5005 mL

15.0010 mL

5 mM

0.3000 mL

1.5001 mL

3.0002 mL

10 mM

0.1500 mL

0.7501 mL

1.5001 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline